Jörn Drappa

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

Richard Furie, Munther A. Khamashta, Joan T. Merrill et al. · Arthritis & Rheumatology · 2016 · 867 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Bruce Cree, Jeffrey L. Bennett, Ho Jin Kim et al. · The Lancet · 2019 · 717 citations

Medicine, Neurology, Pharmacotherapy +4

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Munther A. Khamashta, Joan T. Merrill, Victoria P. Werth et al. · Annals of the Rheumatic Diseases · 2016 · 498 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

<i>Fas</i>Gene Mutations in the Canale–Smith Syndrome, an Inherited Lymphoproliferative Disorder Associated with Autoimmunity

Jörn Drappa, Akshay Vaishnaw, Kathleen E. Sullivan et al. · New England Journal of Medicine · 1996 · 482 citations · Full text

Life Sciences, Genetics, Immunology +16

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study

Eduardo Mysler, Alberto Spindler, Renato Guzmán et al. · Arthritis & Rheumatism · 2013 · 354 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13